Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
170M
-
Number of holders
-
326
-
Total 13F shares, excl. options
-
168M
-
Shares change
-
-2.1M
-
Total reported value, excl. options
-
$3.58B
-
Value change
-
-$45.9M
-
Put/Call ratio
-
0.75
-
Number of buys
-
180
-
Number of sells
-
-136
-
Price
-
$21.34
Significant Holders of ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) as of Q3 2025
387 filings reported holding ACAD - ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value as of Q3 2025.
ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) has 326 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 168M shares
of 170M outstanding shares and own 98.56% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (42.9M shares), BlackRock, Inc. (20.3M shares), VANGUARD GROUP INC (15.2M shares), STATE STREET CORP (7.26M shares), RTW INVESTMENTS, LP (7.14M shares), GEODE CAPITAL MANAGEMENT, LLC (3.13M shares), DIMENSIONAL FUND ADVISORS LP (2.8M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.48M shares), Palo Alto Investors LP (2.47M shares), and BRAIDWELL LP (2.38M shares).
This table shows the top 326 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.